Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine

Roopa Bhat, Sidharth Mahapatra, Robert C. Axtell, Lawrence Steinman

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

In patients with multiple sclerosis, the selective serotonin reuptake inhibitor, fluoxetine, resulted in less acute disease activity. We tested the immune modulating effects of fluoxetine in a mouse model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). We show that fluoxetine delayed the onset of disease and reduced clinical paralysis in mice with established disease. Fluoxetine had abrogating effects on proliferation of immune cells and inflammatory cytokine production by both antigen-presenting cells and T cells. Specifically, in CD4 T cells, fluoxetine increased Fas-induced apoptosis. We conclude that fluoxetine possesses immune-modulating effects resulting in the amelioration of symptoms in EAE.

Original languageEnglish (US)
Pages (from-to)77-81
Number of pages5
JournalJournal of Neuroimmunology
Volume313
DOIs
StatePublished - Dec 15 2017

Fingerprint

Autoimmune Experimental Encephalomyelitis
Fluoxetine
Multiple Sclerosis
T-Lymphocytes
Serotonin Uptake Inhibitors
Acute Disease
Antigen-Presenting Cells
Paralysis
Cell Proliferation
Apoptosis
Cytokines

Keywords

  • EAE
  • Experimental autoimmune encephalomyelitis
  • Fluoxetine
  • Multiple sclerosis
  • Neuroinflammation
  • SSRI

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Neurology
  • Clinical Neurology

Cite this

Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. / Bhat, Roopa; Mahapatra, Sidharth; Axtell, Robert C.; Steinman, Lawrence.

In: Journal of Neuroimmunology, Vol. 313, 15.12.2017, p. 77-81.

Research output: Contribution to journalArticle

Bhat, Roopa ; Mahapatra, Sidharth ; Axtell, Robert C. ; Steinman, Lawrence. / Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine. In: Journal of Neuroimmunology. 2017 ; Vol. 313. pp. 77-81.
@article{66f48e023f1c41e6b70db778c145733e,
title = "Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine",
abstract = "In patients with multiple sclerosis, the selective serotonin reuptake inhibitor, fluoxetine, resulted in less acute disease activity. We tested the immune modulating effects of fluoxetine in a mouse model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). We show that fluoxetine delayed the onset of disease and reduced clinical paralysis in mice with established disease. Fluoxetine had abrogating effects on proliferation of immune cells and inflammatory cytokine production by both antigen-presenting cells and T cells. Specifically, in CD4 T cells, fluoxetine increased Fas-induced apoptosis. We conclude that fluoxetine possesses immune-modulating effects resulting in the amelioration of symptoms in EAE.",
keywords = "EAE, Experimental autoimmune encephalomyelitis, Fluoxetine, Multiple sclerosis, Neuroinflammation, SSRI",
author = "Roopa Bhat and Sidharth Mahapatra and Axtell, {Robert C.} and Lawrence Steinman",
year = "2017",
month = "12",
day = "15",
doi = "10.1016/j.jneuroim.2017.10.012",
language = "English (US)",
volume = "313",
pages = "77--81",
journal = "Journal of Neuroimmunology",
issn = "0165-5728",
publisher = "Elsevier",

}

TY - JOUR

T1 - Amelioration of ongoing experimental autoimmune encephalomyelitis with fluoxetine

AU - Bhat, Roopa

AU - Mahapatra, Sidharth

AU - Axtell, Robert C.

AU - Steinman, Lawrence

PY - 2017/12/15

Y1 - 2017/12/15

N2 - In patients with multiple sclerosis, the selective serotonin reuptake inhibitor, fluoxetine, resulted in less acute disease activity. We tested the immune modulating effects of fluoxetine in a mouse model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). We show that fluoxetine delayed the onset of disease and reduced clinical paralysis in mice with established disease. Fluoxetine had abrogating effects on proliferation of immune cells and inflammatory cytokine production by both antigen-presenting cells and T cells. Specifically, in CD4 T cells, fluoxetine increased Fas-induced apoptosis. We conclude that fluoxetine possesses immune-modulating effects resulting in the amelioration of symptoms in EAE.

AB - In patients with multiple sclerosis, the selective serotonin reuptake inhibitor, fluoxetine, resulted in less acute disease activity. We tested the immune modulating effects of fluoxetine in a mouse model of multiple sclerosis, i.e. experimental autoimmune encephalomyelitis (EAE). We show that fluoxetine delayed the onset of disease and reduced clinical paralysis in mice with established disease. Fluoxetine had abrogating effects on proliferation of immune cells and inflammatory cytokine production by both antigen-presenting cells and T cells. Specifically, in CD4 T cells, fluoxetine increased Fas-induced apoptosis. We conclude that fluoxetine possesses immune-modulating effects resulting in the amelioration of symptoms in EAE.

KW - EAE

KW - Experimental autoimmune encephalomyelitis

KW - Fluoxetine

KW - Multiple sclerosis

KW - Neuroinflammation

KW - SSRI

UR - http://www.scopus.com/inward/record.url?scp=85032280165&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032280165&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2017.10.012

DO - 10.1016/j.jneuroim.2017.10.012

M3 - Article

C2 - 29153612

AN - SCOPUS:85032280165

VL - 313

SP - 77

EP - 81

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

ER -